Published in Eur Respir J on November 14, 2008
Animal models of bronchopulmonary dysplasia. The term mouse models. Am J Physiol Lung Cell Mol Physiol (2014) 1.14
Postnatal inflammation in the pathogenesis of bronchopulmonary dysplasia. Birth Defects Res A Clin Mol Teratol (2014) 1.08
Apelin attenuates hyperoxic lung and heart injury in neonatal rats. Am J Respir Crit Care Med (2010) 1.00
Phosphodiesterase 4 inhibition attenuates persistent heart and lung injury by neonatal hyperoxia in rats. Am J Physiol Lung Cell Mol Physiol (2011) 0.93
Small molecular modulation of macrophage migration inhibitory factor in the hyperoxia-induced mouse model of bronchopulmonary dysplasia. Respir Res (2013) 0.89
Phosphodiesterases: emerging therapeutic targets for neonatal pulmonary hypertension. Handb Exp Pharmacol (2011) 0.87
Caffeine and rolipram affect Smad signalling and TGF-β1 stimulated CTGF and transgelin expression in lung epithelial cells. PLoS One (2014) 0.86
Soluble guanylate cyclase modulates alveolarization in the newborn lung. Am J Physiol Lung Cell Mol Physiol (2013) 0.84
cAMP-mediated secretion of brain-derived neurotrophic factor in developing airway smooth muscle. Biochim Biophys Acta (2015) 0.81
Cigarette Smoke-Induced Emphysema and Pulmonary Hypertension Can Be Prevented by Phosphodiesterase 4 and 5 Inhibition in Mice. PLoS One (2015) 0.80
Synergistic effect of caffeine and glucocorticoids on expression of surfactant protein B (SP-B) mRNA. PLoS One (2012) 0.79
Angiotensin II type 2 receptor ligand PD123319 attenuates hyperoxia-induced lung and heart injury at a low dose in newborn rats. Am J Physiol Lung Cell Mol Physiol (2014) 0.79
Does PDE4 inhibition improve alveolarisation in hyperoxia-exposed immature rodents? Eur Respir J (2009) 0.78
Attenuating endogenous Fgfr2b ligands during bleomycin-induced lung fibrosis does not compromise murine lung repair. Am J Physiol Lung Cell Mol Physiol (2015) 0.78
Fgf10 deficiency is causative for lethality in a mouse model of bronchopulmonary dysplasia. J Pathol (2016) 0.76
Endothelial Monocyte-Activating Polypeptide II Mediates Macrophage Migration in the Development of Hyperoxia-Induced Lung Disease of Prematurity. Am J Respir Cell Mol Biol (2016) 0.75
Influence of prenatal hypoxia and postnatal hyperoxia on morphologic lung maturation in mice. PLoS One (2017) 0.75
Wnt3a Mediates the Inhibitory Effect of Hyperoxia on the Transdifferentiation of AECIIs to AECIs. J Histochem Cytochem (2015) 0.75
The Future of Bronchopulmonary Dysplasia: Emerging Pathophysiological Concepts and Potential New Avenues of Treatment. Front Med (Lausanne) (2017) 0.75
Real-time quantitative RT-PCR after laser-assisted cell picking. Nat Med (1998) 7.34
Oligosaccharides in human milk: structural, functional, and metabolic aspects. Annu Rev Nutr (2000) 3.35
[German guideline for diagnosis and management of idiopathic pulmonary fibrosis]. Pneumologie (2013) 3.03
Sildenafil treatment for portopulmonary hypertension. Eur Respir J (2006) 2.58
Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea. Impact of continuous positive airway pressure therapy. Am J Respir Crit Care Med (2000) 2.55
Reproduction of transfusion-related acute lung injury in an ex vivo lung model. Blood (1990) 2.54
Treprostinil inhibits the recruitment of bone marrow-derived circulating fibrocytes in chronic hypoxic pulmonary hypertension. Eur Respir J (2010) 2.51
Neoalveolarisation contributes to compensatory lung growth following pneumonectomy in mice. Eur Respir J (2007) 2.11
First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J (2009) 2.04
Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med (2000) 1.95
Cold-atom scanning probe microscopy. Nat Nanotechnol (2011) 1.88
Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med (1996) 1.87
Monocytes recruited into the alveolar air space of mice show a monocytic phenotype but upregulate CD14. Am J Physiol Lung Cell Mol Physiol (2001) 1.85
Biological functions of oligosaccharides in human milk. Acta Paediatr (1993) 1.80
Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema. Am J Respir Crit Care Med (1996) 1.79
Aerosolised prostacyclin in adult respiratory distress syndrome. Lancet (1993) 1.74
Structure of the complex formed by bovine trypsin and bovine pancreatic trypsin inhibitor. Crystal structure determination and stereochemistry of the contact region. J Mol Biol (1973) 1.73
A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol (2000) 1.73
The dorsolateral, suboccipital, transcondylar approach to the lower clivus and anterior portion of the craniocervical junction. Neurosurgery (1991) 1.67
Bacterial exotoxins and endothelial permeability for water and albumin in vitro. Am J Physiol (1988) 1.61
Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J (2008) 1.58
Mast cells promote lung vascular remodelling in pulmonary hypertension. Eur Respir J (2010) 1.57
Staphylococcal alpha-toxin-induced PGI2 production in endothelial cells: role of calcium. Am J Physiol (1985) 1.57
Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann Intern Med (2000) 1.57
Phenotypic characterization of alveolar monocyte recruitment in acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol (2000) 1.54
The role of magnesium in the relaxation of myofibrils. Biochemistry (1969) 1.50
Regenerative therapies in neonatology: clinical perspectives. Klin Padiatr (2012) 1.49
Chalcone, acyl hydrazide, and related amides kill cultured Trypanosoma brucei brucei. Mol Med (2000) 1.49
[Sildenafil for treatment of severe pulmonary hypertension and commencing right-heart failure]. Pneumologie (2002) 1.48
Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats. Eur Respir J (2010) 1.47
Long-term outcome with intravenous iloprost in pulmonary arterial hypertension. Eur Respir J (2009) 1.44
Alteration of surfactant function due to protein leakage: special interaction with fibrin monomer. J Appl Physiol (1985) (1985) 1.44
Staphylococcal alpha-toxin elicits hypertension in isolated rabbit lungs. Evidence for thromboxane formation and the role of extracellular calcium. J Clin Invest (1984) 1.43
Biosynthesis of constitutive nitric oxide synthase-derived nitric oxide attenuates coronary vasoconstriction and myocardial depression in a model of septic heart failure induced by Staphylococcus aureus alpha-toxin. Crit Care Med (2001) 1.43
Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med (1996) 1.42
Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis. Ann Neurol (1998) 1.40
Low-grade non-Hodgkin's lymphoma after high-grade non-Hodgkin's lymphoma in a child with ataxia telangiectasia. Cancer (1994) 1.40
Characterisation of post-pneumonectomy lung growth in adult mice. Eur Respir J (2004) 1.39
Nano-carriers for DNA delivery to the lung based upon a TAT-derived peptide covalently coupled to PEG-PEI. J Control Release (2005) 1.38
The effect of repeated ozone exposures on inflammatory markers in bronchoalveolar lavage fluid and mucosal biopsies. Am J Respir Crit Care Med (2000) 1.36
Human milk oligosaccharides are minimally digested in vitro. J Nutr (2000) 1.35
Bronchoalveolar and systemic cytokine profiles in patients with ARDS, severe pneumonia and cardiogenic pulmonary oedema. Eur Respir J (1996) 1.35
Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on biophysical and biochemical surfactant properties. Eur Respir J (2002) 1.35
Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease. Thromb Haemost (2000) 1.33
Monocyte migration through the alveolar epithelial barrier: adhesion molecule mechanisms and impact of chemokines. J Immunol (2000) 1.32
Mechanism of leukotriene generation in polymorphonuclear leukocytes by staphylococcal alpha-toxin. Infect Immun (1987) 1.30
Disinfectant contaminated with Klebsiella oxytoca as a source of sepsis in babies. Lancet (2000) 1.30
Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J (2010) 1.28
The basic trypsin inhibitor of bovine pancreas. I. Structure analysis and conformation of the polypeptide chain. Naturwissenschaften (1970) 1.28
Relationship between arterial and venous Doppler and perinatal outcome in fetal growth restriction. Ultrasound Obstet Gynecol (2000) 1.28
Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on gas exchange and haemodynamics. Eur Respir J (2002) 1.27
Decreased plasma levels of nitric oxide derivatives in obstructive sleep apnoea: response to CPAP therapy. Thorax (2000) 1.27
Surfactant abnormalities in patients with respiratory failure after multiple trauma. Am Rev Respir Dis (1989) 1.27
Regulation of hypoxic pulmonary vasoconstriction: basic mechanisms. Eur Respir J (2008) 1.24
Surfactant alteration and replacement in acute respiratory distress syndrome. Respir Res (2001) 1.23
Human endothelial cell activation and mediator release in response to the bacterial exotoxins Escherichia coli hemolysin and staphylococcal alpha-toxin. J Immunol (1997) 1.23
Hypoxic vasoconstriction in intact lungs: a role for NADPH oxidase-derived H(2)O(2)? Am J Physiol Lung Cell Mol Physiol (2000) 1.22